Clinical Trial: A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC)

U.S., Oct. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07899801) titled 'A Phase 1a/1b Of Zanidatamab In Combination With Zongertinib In HER2-Mutated Non-Small Cell Lung Cancer (NSCLC)' on Oct. 26.

Brief Summary: This is a Phase Ia/Ib, open-label study evaluating the concurrent administration of zanidatamab and zongertinib in patients with advanced, unresectable, or metastatic non-small lung cancer harboring HER2 alterations.

Study Start Date: April 01, 2027

Study Type: INTERVENTIONAL

Condition: Non Small Cell Lung Cancer

Intervention: DRUG: Zanidatamab

Given by intravenous infusion

DRUG: Zongertinib

Given by mouth

Recruitment Status: NOT_YET_RECRUITING

Sponsor: M.D. Anderson Cancer Center

Pu...